Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Sector ratings VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2025-01-14 pm EST 		5-day change 1st Jan Change
2.750 USD -8.94% Intraday chart for VYNE Therapeutics Inc. -35.75% -17.91%
Jan. 06 VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo CI
Dec. 23 VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor MT
Main competitors
Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Composite Fundamentals Composite Valuation Composite Consensus Composite Momentum Composite Visibility Investor Rating ESG MSCI Capi. ($)
VYNE THERAPEUTICS INC. Stock VYNE Therapeutics Inc.
 - - 40.57M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
AA
106B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
A
74.33B
ARGENX SE Stock argenx SE
AA
40.62B
BIONTECH SE Stock BioNTech SE
 - - 26.95B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
AA
21.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
 - - 21.42B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
A
14.12B
GENMAB A/S Stock Genmab A/S
AA
13.79B
INSMED INCORPORATED Stock Insmed Incorporated
 -
BBB
12.22B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
BBB
11.35B
EXELIXIS, INC. Stock Exelixis, Inc.
BB
10.18B
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
AAA
9.28B
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
 - - 7.86B
PHARMAESSENTIA CORPORATION Stock PharmaEssentia Corporation
A
7.26B
ZEALAND PHARMA A/S Stock Zealand Pharma A/S
 -
BBB
6.78B
Average
AA
 23.98B
Weighted average by Cap.
AA
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. Sector VYNE Therapeutics Inc.
  5. Sector ratings